340
Participants
Start Date
September 19, 2024
Primary Completion Date
October 31, 2027
Study Completion Date
October 31, 2027
LY4050784
Oral
Pembrolizumab
Administered IV.
Cisplatin
Administered IV.
Carboplatin
Administered IV.
Pemetrexed
Administered IV.
Paclitaxel
Administered IV.
Nab paclitaxel
Administered IV.
RECRUITING
Columbia University Medical Center, New York
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
NOT_YET_RECRUITING
UPMC Hillman Cancer Center, Pittsburgh
RECRUITING
USO-Virginia Cancer Specialists, PC, Fairfax
RECRUITING
Florida Cancer Specialists ORLANDO/DDU, Lake Mary
RECRUITING
University of Miami, Miami
RECRUITING
Sarah Cannon Research Institute, Nashville
RECRUITING
SCRI Oncology Partners, Nashville
RECRUITING
Ohio State University Hospital, Columbus
RECRUITING
Medical College of Wisconsin, Milwaukee
RECRUITING
University of Chicago, New Lenox
NOT_YET_RECRUITING
University of Colorado Health Hospital, Aurora
RECRUITING
Sarah Cannon Research Institute at HealthOne, Denver
NOT_YET_RECRUITING
UCLA, Santa Monica
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Dana-Farber Cancer Institute, Boston
NOT_YET_RECRUITING
Vanderbilt-Ingram Cancer Center, Nashville
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
National Cancer Center Hospital, Chūōku
RECRUITING
National Cancer Center Hospital East, Kashiwa
RECRUITING
The Cancer Institute Hospital of JFCR, Kōtō City
RECRUITING
Shizuoka Cancer Center, Nagaizumi-cho,Sunto-gun
RECRUITING
Aichi Cancer Center Hospital, Nagoya
Eli Lilly and Company
INDUSTRY